Revance Therapeutics Inc (RVNC)

[radford]

As I said, I expect the CD approval to be based primarily on the strength of the clinical data package. While Revance has had some execution problems with manufacturing, IMO they have done a very thorough job of conducting the clinical trials. I don't recall any FDA issues with glabellar (sp?) lines clinical trials. There are others here who could better comment on the quality of the CD trial data but from my recollection of the results I would consider approval to be highly likely. Maybe that equates to a 90/10 probability of approval.